Title
TECHNETIUM-99m LABELLED STANNOUS-ETHANE-1-HYDROXY-I, 1-DIPHOSPHONATE: A NEW BOMB SCANNING AGENT

Permalink
https://escholarship.org/uc/item/56z0c1f0

Author
Yano, Y.

Publication Date
1971-12-01
TECHNETIUM-99m LABELLED STANNOUS-ETHANE-1-HYDROXY-1, 1-DIPHOSPHONATE: A NEW BONE SCANNING AGENT

Y. Yano, D. C. Van Dyke, J. McRae, and H. O. Anger
DONNER LABORATORY

December 1971

AEC Contract No. W-7405-eng-48

For Reference
Not to be taken from this room
DISCLAIMER

This document was prepared as an account of work sponsored by the United States Government. While this document is believed to contain correct information, neither the United States Government nor any agency thereof, nor the Regents of the University of California, nor any of their employees, makes any warranty, express or implied, or assumes any legal responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by its trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof, or the Regents of the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof or the Regents of the University of California.
Technetium-99m Labelled Stannous-Ethane-1-Hydroxy-1,1-Diphosphonate:

A New Bone Scanning Agent

Y. Yano, D. C. Van Dyke, J. McRae, and H. O. Anger
Lawrence Berkeley Laboratory and
Donner Laboratory
University of California
Berkeley, California 94720
Ethane-1-hydroxy-1,1-diphosphonate (EHDP) has been reported to be biochemically active by chemisorption (1) to hydroxyapatite and the subsequent inhibition of bone crystal formation and resorption (2). It has also been reported to be an effective agent for the treatment of Paget's disease of the bone (3). Because these properties of EHDP indicate bone specificity, we have investigated the usefulness of $^{99m}$Tc labelled Sn-EHDP as a bone scanning agent. Various methods of labelling EHDP with $^{99m}$Tc were investigated to provide a bone specific radiopharmaceutical which makes available the superior scanning characteristics of $^{99m}$Tc, i.e. high yield of 140 keV photons and low radiation dose.

Although initial efforts to label EHDP with $^{99m}$Tc by the zirconium electrolytic method were unsuccessful, a method using stannous tin is effective in labelling EHDP with $^{99m}$Tc.

The chemical mechanism involved is uncertain, but it is probable that an electron transfer process takes place between divalent tin and Tc (a transition metal ion) and a chelating ligand such as tartrate or citrate (3,4), and in this case EHDP.

**Materials and Methods**

The EHDP used for this study was made available through the courtesy of M. D. Francis, A. J. Tofe, and the Procter and Gamble Co.

Reagent grade SnCl$_2$·2H$_2$O is used and freshly prepared in 0.01 N HCl acid just prior to the labelling procedure.

* EHDP; trade name, Procter and Gamble Co.
Commercially available MEK extracted $^{99m}$TcO$_4$ (20 mCi/ml) in isotonic saline is used for the preparation of $^{99m}$Tc-Sn-EHDP.

The method for making $^{99m}$Tc-Sn-EHDP is as follows:

1. Dissolve 10 mg of reagent grade SnCl$_2$·2H$_2$O in 100 ml of 0.01 N HCl acid and filter 1 ml of this solution through a 0.22μ Millipore filter into an evacuated serum vial.

2. Dissolve 5 mg of EHDP in 1 ml of sterile O$_2$-free H$_2$O and add to the 1-ml Sn(II) and mix for 1-2 minutes.

3. Add the desired activity of $^{99m}$TcO$_4$ in 3 ml of saline and mix for 1-2 minutes.

4. Adjust the preparation to pH 6 with dilute NaOH solution.

5. Finally filter the $^{99m}$Tc-Sn-EHDP through a 0.22μ Millipore filter to insure sterility of the preparation.

The $^{99m}$Tc-Sn-EHDP preparation is Tc "carrier free" and contains 1 mg EHDP/ml, 0.02 mg SnCl$_2$·2H$_2$O/ml and 10-15 mCi $^{99m}$Tc/ml. The chemical labelling efficiency is about 95% of the $^{99m}$TcO$_4$ added to the preparation.

The binding efficiency of the chemical labelling procedure and the stability of the preparation were determined by ascending paper chromatography using Whatman #1 paper strips in 85% methanol solvent.

To extend the shelf life of $^{99m}$Tc-Sn-EHDP, the reagent solutions should be made free of dissolved oxygen by saturating the solution with nitrogen and performing the chemical preparation in an evacuated and sealed serum vial. The reagents and glassware used for the preparation are sterile and pyrogen free.
Evaluation of $^{99m}$Tc-Sn-EHDP in Animals

The $^{99m}$Tc-Sn-EHDP compound was evaluated in Sprague-Dawley rats weighing 200-250 grams and in beagle dogs weighing about 10 kg. In rats 0.5 ml of the material was injected intravenously by tail vein, scintillation camera pictures were obtained to visualize the distribution of $^{99m}$Tc-Sn-EHDP at different times after intravenous injection. In rats both the multichannel and 1/8" pinhole collimators were used. In dogs the whole body scanner (5) and/or the tomographic scanner (6) were also used.

Tissue distribution studies were done in rats by administering 0.5-1.0 ml of $^{99m}$Tc-Sn-EHDP and sacrificing the animals at 3 hours and 20 hours.

Blood disappearance half-times were determined in dogs by taking 1-ml blood samples from 1 min to 180 min after administration of the $^{99m}$Tc-Sn-EHDP. The blood samples were counted in a well counter using an NaI(Tl) crystal and the data were plotted on semilog paper to obtain the blood disappearance half-times. A known dilution of the injected dose of $^{99m}$Tc was counted to determine the blood activity at zero time after injection.

Results and Discussion

Table I shows the percent uptake of $^{99m}$Tc from $^{99m}$Tc-Sn-EHDP for whole organs of rat (except skeleton which is represented by femur uptake and blood which is shown as uptake per ml) for 10:1, 50:1, and 100:1 molar ratios of EHDP to SnCl$_2$·2H$_2$O three hr after intravenous injection. The uptake of $^{99m}$Tc in the carcass is primarily skeletal uptake and appears to be optimal at the 50:1 molar ratio of
EHDP:SnCl$_2$$\cdot$2H$_2$O. The percent uptake in the marrow was determined by difference from femur + marrow counts/min less the counts/min of femur alone.

Figure 1 is a composite scintillation camera picture made with the 1/8" diameter pinhole collimator. It shows the $^{99m}$Tc-Sn-EHDP uptake to be primarily in the skeleton of a rat 3 hr after intravenous injection. There is no visible uptake in liver, spleen or stomach. The uptake in the pelvic region is urinary excretion accumulating in the bladder.

Figure 2 shows the uptake in a dog 20 hr after injection of 5 mCi of $^{99m}$Tc-Sn-EHDP. On the left is the posterior view and on the right a lateral view taken with the scintillation camera using the multi-channel collimator.

A number of preparations of $^{99m}$Tc-Sn-EHDP were given to rats and dogs. In each case, when the labelling method described in this paper was followed, good bone imaging was obtained.

Good bone imaging is also obtained in rats when the method of preparation is modified by substituting H$_2$O in place of the 0.01 N HCl acid. This modification simplifies the procedure by eliminating the neutralization step. $^{99m}$Tc-Sn-EHDP prepared by the water method and using $^{14}$C labelled EHDP is being investigated by A. J. Tofe (8).

Variations in the method of preparation of the compound such as increased concentrations of Sn(II) and EHDP resulted in some preparations that localized primarily in the kidneys of rats with retention of the activity in the kidneys even after 24 hr. One of the results of increased concentrations of EHDP (10 mg/ml) and SnII (0.2 mg/ml) is shown in Figure 3.
The high uptake and prolonged retention of $^{99m}$Tc-Sn-EHDP within the kidneys with the ten times greater concentration of EHDP and Sn than used in the standard preparations, indicates an overload factor of EHDP which causes a failure of the renal excretion mechanism. On the other hand, when the described method of preparation was followed, approximately 60-70% of the radioactivity was excreted by way of the kidneys. This excretion was nearly complete at 3 hr. There was little retention of activity within the kidneys which were only faintly visualized by scintillation camera pictures as shown in Figure 1.

Table II shows the distribution of $^{99m}$Tc-Sn-EHDP in the whole organ of rats for variations in the order of addition of the chemical reagents; first by EHDP, Sn(II), $^{99m}$TcO$_4$ and second by Sn(II), $^{99m}$TcO$_4$, EHDP. The tissue distribution was determined at 3 and 20 hr after administration of $^{99m}$Tc-Sn-EHDP. By the first method the uptake in blood, liver, kidneys and gut is relatively low at 3 hr, while the bone uptake is high. However when the second method is used the bone uptake decreases while the blood, liver and kidney uptake increase.

These data indicate that EHDP and SnII form a chelate which has a greater reducing potential than Sn(II) alone and that the Sn(II)-EHDP chelate will combine with the reduced $^{99m}$Tc. On the other hand, when the Sn(II) and $^{99m}$TcO$_4$ are combined first there is an insoluble Sn-$^{99m}$Tc coprecipitate probably as the $^{99m}$Tc coprecipitated with SnO (9). This coprecipitate is not as readily chelated by the EHDP. This is reflected in the increased uptake in liver.

Table III shows the results of diluting the standard $^{99m}$Tc-Sn-EHDP preparation 100-fold. The data indicates a breakdown of the compound in the diluted preparation with a decrease in bone uptake.
and an increase in soft tissue uptake.

The blood disappearance curves can be approximated with at least two components with $T_{1/2} = 120$ min and $T_{1/2} = 17$ min.

The method of using Sn(II) for labelling EHDP with $^{99m}$Tc is dependent upon the ability of chelating agents to stabilize Sn(II) and increase its usefulness as a reducing agent for $^{99m}$TcO$_4^-$. Further the stability of the $^{99m}$Tc-Sn-EHDP preparation in vivo minimizes Sn colloid formation at neutral pH and also minimizes the binding of Sn-$^{99m}$Tc to blood proteins.

The stability of the $^{99m}$Tc-Sn-EHDP in vitro is dependent upon removing air, i.e. oxygen, from the preparation. The initial chemical binding efficiency ranges from 90-96% and the amount of $^{99m}$Tc still bound to Sn-EHDP after 6 hr is 85-90% in an O$_2$-free system. When the O$_2$ is not excluded, the preparation breaks down within 2-4 hr to about 65-75% $^{99m}$Tc bound to Sn-EHDP.

The estimated radiation dose delivered to a 70 kg patient from $10$ mCi of $^{99m}$Tc-Sn-EHDP for the standard acid method of preparation is:

- $D_{\beta,\gamma}$ (whole body) = 0.148 rad
- $D_{\beta,\gamma}$ (skeleton) = 0.267 rad
- $D_{\beta,\gamma}$ (kidneys) = 3.68 rad
- $D_{\beta,\gamma}$ (bladder) = 7.36 rad

The bladder is the major target organ. The skeletal uptake is estimated to be 30% of the injected dose 3 hr after intravenous administration and the urinary excretion is about 70%.

The amounts of Sn(II) as SnCl$_2$·2H$_2$O and EHDP administered to a 70 kg patient for 10 mCi of $^{99m}$Tc-Sn-EHDP are well below the toxic
levels for Sn(II) and therapeutic levels for EHDP.

Summary

A method has been described for labelling Sn-EHDP with $^{99m}$Tc to provide a bone specific radiopharmaceutical which makes available the superior scanning characteristics of $^{99m}$Tc. Preliminary results in animal studies indicate that $^{99m}$Tc-Sn-EHDP will be extremely useful as a bone scanning agent because of its high uptake in bone, rapid disappearance from blood and soft tissues, and low radiation dose to the patient.

The concentrations of Sn(II) and EHDP as well as the order of addition of the reagents are important factors in determining the $\textit{in vivo}$ distribution of the radiopharmaceutical. $\textit{In vitro}$ stability is dependent upon an $O_2$-free environment for the preparation. Further studies are being done on the chemistry, stability, and biological distribution of $^{99m}$Tc-Sn-EHDP (10).

Acknowledgments

The authors wish to thank M. D. Francis, A. J. Tofe and the Procter and Gamble Co. for the EHDP they kindly furnished. This work was supported by the U. S. Atomic Energy Commission.
References


8. Tofe, A. J.: Personal communication.


10. Francis, M. D.: (personal communication).
TABLE I

Percent Uptake of $^{99m}$Tc from $^{99m}$Tc-Sn-EHDP Per Whole Organ of Rat for Varying Molar Ratios of EHDP:SnCl$_2$·2H$_2$O

Three Hours After Intravenous Injection.

<table>
<thead>
<tr>
<th>Organ</th>
<th>Molar Ratio EHDP:SnCl$_2$·2H$_2$O</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10:1$^+$</td>
</tr>
<tr>
<td>Blood</td>
<td>0.023/ml</td>
</tr>
<tr>
<td>Heart</td>
<td>0.009</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.044</td>
</tr>
<tr>
<td>Liver</td>
<td>0.173</td>
</tr>
<tr>
<td>Kidneys</td>
<td>1.30</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.012</td>
</tr>
<tr>
<td>Gut</td>
<td>1.40</td>
</tr>
<tr>
<td>Muscle of femur</td>
<td></td>
</tr>
<tr>
<td>Marrow + femur</td>
<td>1.08</td>
</tr>
<tr>
<td>Marrow (by diff.)</td>
<td>0.07</td>
</tr>
<tr>
<td>Femur</td>
<td>1.01</td>
</tr>
<tr>
<td>Carcass</td>
<td>35.7</td>
</tr>
</tbody>
</table>

+ mean of 2 rats, 0.5 mg EHDP/kg rat.

* mean of 4 rats, 5 mg EHDP/kg rat.

† mean of 2 rats, 5 mg EHDP/kg rat.
TABLE II
Percent Uptake of $^{99m}$Tc from $^{99m}$Tc-Sn-EHDP Per Whole Organ of Rat for EHDP-Sn(II)-$^{99m}$Tc and for Sn(II)-$^{99m}$Tc-EHDP Preparations in Order of Reagent Addition.

<table>
<thead>
<tr>
<th>Organ</th>
<th>3 Hours EHDP-Sn(II)-$^{99m}$Tc</th>
<th>3 Hours Sn(II)-$^{99m}$Tc-EHDP</th>
<th>20 Hours EHDP-Sn(II)-$^{99m}$Tc*</th>
<th>20 Hours Sn(II)-$^{99m}$Tc-EHDP*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>0.047/ml</td>
<td>0.430/ml</td>
<td>0.008/ml</td>
<td>0.087/ml</td>
</tr>
<tr>
<td>Heart</td>
<td>0.015</td>
<td>0.125</td>
<td>0.004</td>
<td>0.030</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.104</td>
<td>0.409</td>
<td>0.019</td>
<td>0.137</td>
</tr>
<tr>
<td>Liver</td>
<td>0.273</td>
<td>11.41</td>
<td>0.223</td>
<td>10.3</td>
</tr>
<tr>
<td>Kidneys</td>
<td>1.04</td>
<td>2.77</td>
<td>0.910</td>
<td>2.70</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.020</td>
<td>0.280</td>
<td>0.015</td>
<td>0.304</td>
</tr>
<tr>
<td>Gut</td>
<td>0.698</td>
<td>1.72</td>
<td>0.672</td>
<td>1.41</td>
</tr>
<tr>
<td>Marrow + femur</td>
<td>2.11</td>
<td>1.22</td>
<td>1.63</td>
<td>1.13</td>
</tr>
<tr>
<td>Marrow (by diff.)</td>
<td></td>
<td></td>
<td>0.13</td>
<td>0.06</td>
</tr>
<tr>
<td>Femur</td>
<td></td>
<td>1.49</td>
<td>1.07</td>
<td></td>
</tr>
<tr>
<td>Carcass</td>
<td>33.5</td>
<td>33.3</td>
<td>30.4</td>
<td>26.8</td>
</tr>
</tbody>
</table>

* mean of 2 rats, 5.0 mg EHDP/kg rat.
* mean of 2 rats, 5.0 mg EHDP/kg rat.
* one rat, 5.0 mg EHDP/kg rat.
### TABLE III

Percent Uptake of $^{99m}$Tc from $^{99m}$Tc-Sn-EHDP Per Whole Organ of Rat for Standard 50:1, EHDP:SnII, for Undiluted and 100 Times Dilution of Preparation at 3 Hrs.

<table>
<thead>
<tr>
<th>Organ</th>
<th>Undiluted*</th>
<th>100X Dilution†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>0.062</td>
<td>0.201</td>
</tr>
<tr>
<td>Heart</td>
<td>0.025</td>
<td>0.069</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.115</td>
<td>0.262</td>
</tr>
<tr>
<td>Liver</td>
<td>0.272</td>
<td>2.74</td>
</tr>
<tr>
<td>Kidneys</td>
<td>0.954</td>
<td>9.27</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.013</td>
<td>0.055</td>
</tr>
<tr>
<td>Gut</td>
<td>0.897</td>
<td>26.88</td>
</tr>
<tr>
<td>Marrow + Femur</td>
<td>1.65</td>
<td>0.551</td>
</tr>
<tr>
<td>Carcass</td>
<td>46.4</td>
<td></td>
</tr>
</tbody>
</table>

* 5 mg EHDP/kg rat.

† 0.05 mg EHDP/kg rat.
Figure Captions

Figure 1. Scintillation camera picture of a rat 3 hr after administration of $^{99m}$Tc-Sn-EHDP. The rat received 1 mg of EHDP. A 1/8" pinhole collimator was used.

Figure 2. Scintillation camera picture of a dog from posterior and lateral views 20 hr after intravenous administration of 5 mCi of $^{99m}$Tc-Sn-EHDP. The dog received 1 mg of EHDP.

Figure 3. Distribution of non-standard $^{99m}$Tc-Sn-EHDP preparation in a rat 24 hr after administration. A composite of 1/8" pinhole collimator pictures. Note retention in kidneys even after 24 hr. The rat received 10 mg of EHDP and 0.2 mg Sn(II).
Fig. 2
This report was prepared as an account of work sponsored by the United States Government. Neither the United States nor the United States Atomic Energy Commission, nor any of their employees, nor any of their contractors, subcontractors, or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness or usefulness of any information, apparatus, product or process disclosed, or represents that its use would not infringe privately owned rights.